New cancer clinical trial: Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

Published on: February 27, 2018 at 12:00PM
Condition:   Breast Neoplasm Female
Interventions:   Drug: Fulvestrant 500mg;   Drug: Palbociclib 125mg;   Drug: Goserelin 3.6 MG;   Drug: Placebos
Sponsors:   International Cancer Research Group, United Arab Emirates;   AstraZeneca;   Pfizer;   Genomic Health®, Inc.
Recruiting
http://ift.tt/2oyEk0e